SCHEMBL5364504

SCHEMBL5364504

c1cc(OCC2CO2)cc(-c2noc3ncccc23)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.52
ALDH1A1 P00352 3/20 0.52
TSHR P16473 3/20 0.52
HIF1A Q16665 2/20 0.52
CYP3A4 P08684 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TDP1 Q9NUW8 1/20 0.43
PTPN1 P18031 1/20 0.36
FGFR1 P11362 1/20 0.36
SRC P12931 1/20 0.36
CHRNB1 P11230 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNB3 Q05901 1/20 0.34
HPGD P15428 3/20 0.34
MAPT P10636 2/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
PKM P14618 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5364494 1.00 TP53 (0.52) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL5368549 0.79 DYRK1A (0.53) TP53ALDH1A1CYP3A4SMN1; SMN2TDP1
SCHEMBL5366883 0.77 ALDH1A1 (0.50) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL5363261 0.77 ALDH1A1 (0.50) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL5363265 0.77 ALDH1A1 (0.50) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL5364506 0.77 ALDH1A1 (0.47) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL13898700 0.74 TP53 (0.51) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL13898689 0.74 TP53 (0.51) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL23868691 0.73 ALDH1A1 (0.70) TP53ALDH1A1TSHRHIF1ACYP3A4
SCHEMBL14527080 0.73 ALDH1A1 (0.60) TP53ALDH1A1TSHRHIF1ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253165-B2 Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTICALS INC. (US) 2007-08-07 US disclosed
US-20050107377-A1 Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMACEUTIALS INC. (US) 2005-05-19 US disclosed
EP-1216244-B1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists AVENTIS PHARMA INC (US) 2003-08-13 EP disclosed
EP-1216244-A1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists Aventis Pharmaceuticals Inc. (US) 2002-06-26 EP disclosed
WO-2001019821-A1 BENZISOXAZOLYL-, PYRIDOISOXAZOLYL- AND BENZTHIENYL-PHENOXY DERIVATIVES USEFUL AS D4 ANTAGONISTS AVENTIS PHARMACEUTICALS INC. (US) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107377-A1 Benzisoxazolyl-,pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists DRD4, DRD2, DRD1 TP53 3926/4885ALDH1A1 895/4885TSHR 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.